CClinicalTrials.gg
CompletedNCT03127163Updated Apr 25, 2017

Intraestromal Corneal Ring in Mild Keratoconus

An interventional study of Intraestromal corneal ring in Cornea, Eye Diseases and Keratoconus, sponsored by University of Sao Paulo. Completed at 1 site in Brazil. Open to participants aged 17 Years to 47 Years. Per ClinicalTrials.gov, last updated 2017-04-25.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2015, registered Apr 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
17 Years to 47 Years
Sex
All
01

Study summary

To determine whether the implantation of an intrastromal corneal ring is an effective treatment for a homogeneous group of mild keratoconus patients.

Read the detailed description

A group of 65 patients with mild keratoconus were implanted with a Ferrara ring in a single eye. Six months after surgery, the aberrations were measured and the visual function was determined using clinical indices. The aberrations, especially comatic aberration (coma), were measured independently.

02

Conditions studied

  • Cornea
  • Eye Diseases
  • Keratoconus
  • Ophthalmological Disorder
03

In context

Eye Diseases

740 studies on the registry are indexed under Eye Diseases; 117 are open to participants now.

This study's enrollment of 65 is close to the median of 68 across 547 interventional studies indexed under Eye Diseases.

Browse Eye Diseases studies →

Lead sponsor

University of Sao Paulo is the lead sponsor of 1,005 studies on the registry; 90 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 47 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Investigators used the Amsler-Krumeich classification and included only patients classified as grade I or II.

Exclusion criteria

Exclusion Criteria:

  • Investigators excluded patients with central corneal scarring, with other eye disorders, or with previous ocular surgery. We also excluded patients with a history of herpes infection, keratitis, corneal dystrophies, diagnoses of autoimmune diseases, systemic connective tissue disorders, or acute keratoconus.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Other
    Mild Keratoconus

    A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution. We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group.

    Device: Intraestromal corneal ring

Interventions

  • DeviceIntraestromal corneal ring

    The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.

    Also known as: Ferrara ring

06

What researchers measure

Primary outcomes

  1. Aberrations were measured and the visual function was determined using clinical indices.

    Wave front data

    Time frame: 3 months after surgery

Secondary outcomes

  1. UCVA

    Uncorrected visual acuity

    Time frame: 3 months after surgery

  2. BCVA

    Best corrected visual acuity

    Time frame: 3 months after surgery

07

Study locations

1 site
  • Hospital das Clínicas
    Sao Paulo, SP 05403-000, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03127163
Lead sponsor
University of Sao Paulo
Responsible party
Mário Henrique Camargos de Lima (PhD, University of Sao Paulo) — Principal investigator
First posted
Apr 25, 2017
Start date
Jan 10, 2015
Primary completion
Jan 10, 2016
Completion
Jan 10, 2017
Last update
Apr 25, 2017

Study contacts

Mário Lima, PhD
principal investigator · São Paulo University investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion